CELC

+ Watchlist + Portfolio

Celcuity Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $75.13
52-Week Range: $45.03 – $151.02
Market Cap: $3.53B
P/E (TTM): —
EPS (TTM): -4.31
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: -1433.70%
Return on Assets: -25.78%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 8.93
Debt/Equity: —
Total Debt: $754.39M
Free Cash Flow: $-72.00M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $3.53B

CELC Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$35.29M	$60.59M	$104.20M	$145.00M
Selling, General & Admin	$4.10M	$5.64M	$9.06M	$27.20M
Operating Expenses	$39.39M	$66.23M	$113.27M	$172.19M
Operating Income	-$39.39M	-$66.23M	-$113.27M	-$172.19M
EBITDA	-$38.05M	-$58.31M	-$101.37M	-$159.73M
Pretax Income	-$40.37M	-$63.78M	-$111.78M	-$177.04M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$40.37M	-$63.78M	-$111.78M	-$177.04M
Diluted EPS	-2.64	-2.69	-2.83	-3.79
Diluted Shares	15.42M	23.68M	39.45M	46.76M

CELC Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$24.57M	$30.66M	$22.52M	$165.70M
Receivables	$0.00	$805.88K	$1.60M	—
Current Assets	$175.19M	$190.59M	$244.57M	$465.66M
Total Assets	$175.70M	$191.22M	$245.12M	$466.56M
Current Liabilities	$6.88M	$14.19M	$31.72M	$44.15M
Long-Term Debt	$34.98M	$37.04M	$97.73M	$321.85M
Total Debt	$35.24M	$37.45M	$97.95M	$321.90M
Total Liabilities	$41.93M	$51.45M	$129.50M	$366.00M
Retained Earnings	-$96.30M	-$160.08M	-$271.86M	-$448.90M
Shareholders' Equity	$133.77M	$139.77M	$115.62M	$100.56M
Working Capital	$168.31M	$176.40M	$212.85M	$421.51M
Net Debt	$10.41M	$6.37M	$75.21M	$156.15M

CELC Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$36.01M	-$53.81M	-$83.47M	-$153.28M
Capital Expenditure	-$158.77K	-$97.64K	-$250.00K	-$249.00K
Free Cash Flow	-$36.17M	-$53.91M	-$83.72M	-$153.53M
Depreciation & Amortisation	$210.92K	$142.77K	$130.00K	$167.00K
Stock-Based Compensation	$4.64M	$4.90M	$6.99M	$21.38M
Investing Cash Flow	-$144.03M	-$5.01M	-$63.07M	-$64.08M
Financing Cash Flow	$120.33M	$64.91M	$138.39M	$360.55M
Net Change in Cash	-$59.71M	$6.09M	-$8.15M	$143.19M

CELC Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$29.76M	$36.41M	$34.91M	$37.63M	$33.06M	$31.08M
Selling, General & Admin	$6.37M	$7.59M	$7.93M	$11.57M	$17.44M	$35.04M
Operating Expenses	$36.13M	$44.01M	$42.85M	$49.20M	$50.51M	$66.12M
Operating Income	-$36.13M	-$44.01M	-$42.85M	-$49.20M	-$50.51M	-$66.12M
EBITDA	-$33.78M	-$42.02M	-$39.17M	-$44.76M	-$46.71M	-$73.38M
Pretax Income	-$37.00M	-$45.27M	-$43.80M	-$50.97M	-$52.84M	-$78.86M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$37.00M	-$45.27M	-$43.80M	-$50.97M	-$52.84M	-$78.86M
Diluted EPS	-0.86	-1.04	-0.92	-0.97	-0.97	-1.44
Diluted Shares	43.05M	43.66M	47.59M	52.54M	54.46M	54.82M

CELC Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$16.48M	$46.35M	$74.25M	$165.70M	$145.19M	$182.05M
Current Assets	$217.60M	$183.10M	$475.50M	$465.66M	$408.93M	$775.84M
Total Assets	$218.13M	$183.59M	$476.00M	$466.56M	$410.16M	$828.22M
Current Liabilities	$32.92M	$39.94M	$38.79M	$44.15M	$33.21M	$86.87M
Long-Term Debt	$98.53M	$99.28M	$320.25M	$321.85M	$323.43M	$753.24M
Total Debt	$98.71M	$99.42M	$320.35M	$321.90M	$323.44M	$754.38M
Total Liabilities	$131.46M	$139.22M	$359.04M	$366.00M	$356.64M	$841.00M
Retained Earnings	-$308.85M	-$354.12M	-$397.92M	-$448.90M	-$501.74M	-$580.60M
Shareholders' Equity	$86.67M	$44.38M	$116.96M	$100.56M	$53.52M	-$12.78M
Working Capital	$184.68M	$143.16M	$436.70M	$421.51M	$375.72M	$688.97M
Net Debt	$82.05M	$52.92M	$246.00M	$156.15M	$178.24M	$571.19M

CELC Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$35.85M	-$36.21M	-$44.82M	-$36.40M	-$55.06M	-$55.43M
Capital Expenditure	-$60.00K	-$39.00K	-$97.00K	-$53.00K	-$285.00K	-$136.00K
Free Cash Flow	-$35.91M	-$36.25M	-$44.91M	-$36.45M	-$55.35M	-$55.56M
Depreciation & Amortisation	$37.00K	$40.00K	$41.00K	$49.00K	$47.00K	$59.00K
Stock-Based Compensation	$2.44M	$2.70M	$6.78M	$9.46M	$5.33M	$6.90M
Investing Cash Flow	$24.26M	$65.86M	-$257.61M	$103.41M	$34.52M	-$330.59M
Financing Cash Flow	$5.55M	$232.00K	$330.32M	$24.44M	$34.00K	$422.87M
Net Change in Cash	-$6.04M	$29.88M	$27.90M	$91.45M	-$20.51M	$36.86M

Market Snapshot

About

Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for cancer patients, headquartered in Minneapolis, Minnesota. The company's lead product candidate, gedatolisib, is a dual PI3K/mTOR inhibitor being evaluated in combination with other agents for the treatment of advanced breast cancer and other solid tumors. Celcuity utilizes its proprietary CELsignia diagnostic platform to identify cancer patients most likely to benefit from specific targeted therapies based on cellular signaling pathway analysis. The company is conducting clinical trials to evaluate gedatolisib in patients with HR-positive, HER2-negative metastatic breast cancer. Celcuity aims to improve patient outcomes by matching targeted therapies to patients whose tumors exhibit specific molecular characteristics.